Join MDA's 75th Anniversary: Advocate, Support, and Transform Lives
Created: May 27, 2025, 8:42 a.m. | Seen by us: Aug. 21, 2025, 1:10 p.m.
meta description if known - MDA celebrates 75 years of advocacy, research, and community support for muscular dystrophy, ALS, and related neuromuscular diseases.
More Details
- h1s:
- 75 YEARS OF Legacy. Impact. Momentum.
- h2s:
- 1949
- 1950
- 1952
- 1952
- 1952
- 1952
- 1953
- 1953
- 1955
- 1955
- 1956
- 1966
- 1971
- 1983
- 1986
- 1986
- 1988
- 1990
- 1992
- 1993
- 1995
- 1996
- 1998
- 1999
- 2000
- 2001
- 2001
- 2003
- 2006
- 2006
- 2007
- 2010
- 2011
- 2015
- 2015
- 2015
- 2016
- 2016
- 2017
- 2017
- 2017
- 2018
- 2018
- 2018
- 2018/2019
- 2019
- 2019
- 2019
- 2020
- 2020
- 2020
- 2020
- 2020
- 2021
- 2021
- 2021
- 2021
- 2021
- 2021
- 2022
- 2022
- 2022
- 2022
- 2022
- 2022
- 2023
- 2023
- 2023
- 2023
- 2023
- 2023
- 2023
- 2023
- 2023
- 2024
- 2024
- 2024
- 2024
- 2024
- 2024
- 1949
- 1950
- 1952
- 1952
- 1952
- 1952
- 1953
- 1953
- 1955
- 1955
- 1956
- 1966
- 1971
- 1983
- 1986
- 1986
- 1988
- 1990
- 1992
- 1993
- 1995
- 1996
- 1998
- 1999
- 2000
- 2001
- 2001
- 2003
- 2006
- 2006
- 2007
- 2010
- 2011
- 2015
- 2015
- 2015
- 2016
- 2017
- 2018
- 2018
- 2018
- 2018/2019
- 2019
- 2019
- 2019
- 2020
- 2020
- 2020
- 2020
- 2021
- 2021
- 2021
- 2022
- 2022
- 2022
- 2022
- 2022
- 2023
- 2023
- 2023
- 2023
- 2024
- 2024
- 2024
- 2024
- 2024
- Join the Movement
- h3s:
- The legacy of a community committed
- Dr. Ade Milhorat is one of few doctors researching muscular dystrophies worldwide
- The Muscular Dystrophy Association of America is founded
- Dean Martin, Jerry Lewis promote MDA on national radio
- MDA Ambassador Program launched
- Five MDA Local Telethons Held in Two Years
- The International Association Resolves to Fight Muscular Dystrophy and "Fills the Boot"
- The first MDA Care Centers are established
- National Association of Letter Carriers becomes MDA's first national sponsor
- Eleanor Gehrig named MDA's National Campaign Chairperson
- MDA holds first MDA Summer Camp
- Martin and Lewis Local Telethon for MDA at Carnegie Hall
- MDA's Legendary Labor Day Telethon Series Begins
- MDA Labor Day Telethon seen across the country
- The Orphan Drug Act (ODA) of 1983 enacted.
- CITGO Joins Forces with MDA
- MDA-funded discovery of the DMD gene launches a new era in genetic research and therapies.
- MDA funds SMA Cell Bank to advance gene discovery
- Americans with Disabilities Act (ADA) signed into law
- Genetic mutations causing myotonic dystrophy type 1 identified
- Mutations in PMP22 identified as a causative for CMT1A
- FDA approves Riluzole, first treatment for ALS
- American Medical Association honors MDA with the Lifetime Achievement Award
- MDA-funded work leads to three FDA-approved exon skipping drugs for Duchenne muscular dystrophy
- MDA funds first clinical trial for gene therapy for any type of muscular dystrophy.
- MDA funds research to boost SMN2 gene expression for SMA treatment.
- Genetic mutation causing myotonic dystrophy type 2 identified.
- U.S. Congress Passes the MD-CARE Act
- The Centers of Excellence program in muscular dystrophy research is established by NIH
- MDA funds the first-ever gene therapy trial for Duchenne muscular dystrophy
- FDA approves Lumizyme (alglucosidase alfa) for the treatment of Pompe Disease
- MDA funds Dr. Adrian Krainer's antisense therapy research, leading to Spinraza for SMA
- Surveying New Therapeutive Avenues
- Identification of C9ORF mutations in ALS
- MDA makes the difficult decision to end its historic Telethon tradition
- FDA approves Keveyis for treating periodic paralysis
- MDA establishes the MDA Resource Center to provide trusted guidance and support nationwide
- FDA approves Exondys 51 (eteplirsen) for the treatment of DMD
- FDA approves Spinraza (nusinersen) for the treatment of SMA
- FDA approves Emflaza (deflazacort) for the treatment of Duchenne Muscular Dystrophy
- FDA approves Radicava (edaravone) for the treatment of ALS
- FDA approves Soliris (eculizumab) for the treatment of myasthenia gravis
- Decoding Disease Mechanisms
- MDA launches the MOVR Data Hub™
- Adrian Krainer, PhD, wins Breakthrough Prize for developing Spinraza, an SMA therapy
- FDA approves Firdapse/Ruzurgi (amifampridine) for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS)
- FDA approves Zolgensma (onasemnogenebeparvovec-xioi) for the treatment of SMA
- FDA approves Vyondys 53 (golodirsen) for the treatment of Duchenne muscular dystrophy
- MDA Hosts First Clinical and Scientific Conference
- FDA approves Viltepso (viltolarsen) to treat Duchenne muscular dystrophy
- FDA approves Evrysdi (risdiplam) to treat spinal muscular atrophy
- Congress passes the ALS Disability Insurance Access Act
- MDA launches Let's Play
- MDA introduces MDA Virtual Summer Camp
- FDA approves Vyvgart (efgartigimod alfa-fcab) to treat generalized myasthenia gravis.
- FDA approves Amondys 45 (casimersen) to treat Duchenne muscular dystrophy
- FDA approves Octagam 10% [Immune Globulin Intraveneous (Human)] to treat adult dermatomyositis
- FDA approves Nexviazyme (avalglucosidase alfa-ngpt) to treat late-onset Pompe disease
- Congress passes the ACT for ALS
- MDA establishes the MDA Mentorship Program
- FDA approves Ultomiris (ravulizumab-cwvz) to treat generalized myasthenia gravis
- FDA approves Relyvrio (sodium phenylbutyrate/taurursodiol) to treat ALS
- MDA introduces the Quest Media Lifestyle platform
- MDA Advocacy Collaboration Grant program launched
- The Centers for Medicare and Medicaid Services creates new diagnostic codes for LGMD
- Congress passes the FDA User Fee Reauthorization Act
- FDA approves Agamree (vamorolone) to treat Duchenne muscular dystrophy
- FDA approves Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) 65mg capsules for adults living with late-onset Pompe disease
- FDA approves Rystiggo (rozanolixizumab-noli) to treat generalized myasthenia gravis
- FDA approves Qalsody (tofersen) to treat ALS
- FDA approves Skyclaris (omaveloxolone) to treat Friederich's ataxia
- MDA Kickstart Program launched
- MDA creates the Gene Therapy Support Network
- MDA establishes MDA Connect
- MDA Introduces Family Getaways Program
- A new era of treatment for neuromuscular diseases emerges
- FDA approves Duvyzat (givinostat) to treat Duchenne muscular dystrophy
- MDA Gene Therapy Support Network honored at 2024 Advanced Therapies Awards
- Congress Passes Air Travel Accessibility Reforms
- All 50 states and DC implement newborn screening for SMA
- MDA College Scholarship Program Established
- The legacy of a community committed
- Dr. Ade Milhorat is one of few doctors researching muscular dystrophies worldwide
- The Muscular Dystrophy Association of America is founded
- Dean Martin, Jerry Lewis promote MDA on national radio
- MDA Ambassador Program launched
- Five MDA Local Telethons Held in Two Years
- The International Association Resolves to Fight Muscular Dystrophy and "Fills the Boot"
- The first MDA Care Centers are established
- National Association of Letter Carriers becomes MDA's first national sponsor
- Eleanor Gehrig named MDA's National Campaign Chairperson
- MDA holds first MDA Summer Camp
- Martin and Lewis Local Telethon for MDA at Carnegie Hall
- MDA's Legendary Labor Day Telethon Series Begins
- MDA Labor Day Telethon seen across the country
- The Orphan Drug Act (ODA) of 1983 enacted.
- CITGO Joins Forces with MDA
- MDA-funded discovery of the DMD gene launches a new era in genetic research and therapies.
- MDA funds SMA Cell Bank to advance gene discovery
- Americans with Disabilities Act (ADA) signed into law
- Genetic mutations causing myotonic dystrophy type 1 identified
- Mutations in PMP22 identified as a causative for CMT1A
- FDA approves Riluzole, first treatment for ALS
- American Medical Association honors MDA with the Lifetime Achievement Award
- MDA-funded work leads to three FDA-approved exon skipping drugs for Duchenne muscular dystrophy
- MDA funds first clinical trial for gene therapy for any type of muscular dystrophy
- MDA funds research to boost SMN2 gene expression for SMA treatment.
- Genetic mutation causing myotonic dystrophy type 2 identified.
- U.S. Congress Passes the MD-CARE Act
- The Centers of Excellence program in muscular dystrophy research is established by NIH
- MDA funds the first-ever gene therapy trial for Duchenne muscular dystrophy
- FDA approves Lumizyme (alglucosidase alfa) for the treatment of Pompe Disease
- MDA funds Dr. Adrian Krainer's antisense therapy research, leading to Spinraza for SMA
- Surveying New Therapeutive Avenues
- Identification of C9ORF mutations in ALS
- MDA makes the difficult decision to end its historic Telethon tradition
- FDA approves Keveyis for treating periodic paralysis
- MDA establishes the MDA Resource Center to provide trusted guidance and support nationwide
- FDA approves Exondys 51 (eteplirsen) for the treatment of DMD
- FDA approves Spinraza (nusinersen) for the treatment of SMA
- FDA approves Emflaza (deflazacort) for the treatment of Duchenne Muscular Dystrophy
- FDA approves Radicava (edaravone) for the treatment of ALS
- FDA approves Soliris (eculizumab) for the treatment of myasthenia gravis
- Decoding Disease Mechanisms
- MDA launches the MOVR Data Hub™
- Adrian Krainer, PhD, wins Breakthrough Prize for developing Spinraza, an SMA therapy
- FDA approves Firdapse/Ruzurgi (amifampridine) for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS)
- FDA approves Zolgensma (onasemnogenebeparvovec-xioi) for the treatment of SMA
- FDA approves Vyondys 53 (golodirsen) for the treatment of Duchenne muscular dystrophy
- MDA Hosts First Clinical and Scientific Conference
- FDA approves Viltepso (viltolarsen) to treat Duchenne muscular dystrophy
- FDA approves Evrysdi (risdiplam) to treat spinal muscular atrophy
- Congress passes the ALS Disability Insurance Access Act
- MDA launches Let's Play
- MDA introduces MDA Virtual Summer Camp
- FDA approves Vyvgart (efgartigimod alfa-fcab) to treat generalized myasthenia gravis.
- FDA approves Amondys 45 (casimersen) to treat Duchenne muscular dystrophy
- FDA approves Octagam 10% [Immune Globulin Intraveneous (Human)] to treat adult dermatomyositis
- FDA approves Nexviazyme (avalglucosidase alfa-ngpt) to treat late-onset Pompe disease
- Congress passes the ACT for ALS
- MDA establishes the MDA Mentorship Program
- FDA approves Ultomiris (ravulizumab-cwvz) to treat generalized myasthenia gravis
- FDA approves Relyvrio (sodium phenylbutyrate/taurursodiol) to treat ALS
- MDA introduces the Quest Media Lifestyle platform
- MDA Advocacy Collaboration Grant program launched
- The Centers for Medicare and Medicaid Services creates new diagnostic codes for LGMD
- Congress passes the FDA User Fee Reauthorization Act
- FDA approves Agamree (vamorolone) to treat Duchenne muscular dystrophy
- FDA approves Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) 65mg capsules for adults living with late-onset Pompe disease
- FDA approves Rystiggo (rozanolixizumab-noli) to treat generalized myasthenia gravis
- FDA approves Qalsody (tofersen) to treat ALS
- FDA approves Skyclaris (omaveloxolone) to treat Friederich's ataxia
- MDA Kickstart Program launched
- MDA creates the Gene Therapy Support Network
- MDA establishes MDA Connect
- MDA Introduces Family Getaways Program
- A new era of treatment for neuromuscular diseases emerges
- FDA approves Duvyzat (givinostat) to treat Duchenne muscular dystrophy
- MDA Gene Therapy Support Network honored at 2024 Advanced Therapies Awards
- Congress Passes Air Travel Accessibility Reforms
- All 50 states and DC implement newborn screening for SMA
- MDA College Scholarship Program Established
- Get Involved
- Make a Gift
- Become an Advocate
- Sign Up for MDA News & Updates
- title: Join MDA's 75th Anniversary: Advocate, Support, and Transform Lives
- emails:
- robots: max-image-preview:large
- keywords: MDA 75th anniversary, muscular dystrophy, advocacy, community support, ALS, gene therapy, research, donate
- og_title: Join MDA's 75th Anniversary: Advocate, Support, and Transform Lives
- addresses:
- 1966 by a single station, WNEW-TV in New York
- 72 gene mutation as the most common genetic cause of AL
- and new paths for MD
- 1966 by a single station, WNEW-TV in New York
- 72 gene mutation as the most common genetic cause of AL
- and new paths for MD
- canonical: https://mda75.org/
- text_size: 61412
- rta_rating: None
- h1_analysis: ok
- h2_analysis: 147 found
- og_site_name: MDA 75th Anniversary
- url_analysis:
- phone_numbers:
- 60607 800-572-1717
- 2017. 2017
- summary_issues:
- title: long
- title_analysis: long
- cc_2025_43_count: 1
- meta_description: MDA celebrates 75 years of advocacy, research, and community support for muscular dystrophy, ALS, and related neuromuscular diseases.
- canonical_analysis: self-referencing
- responsive_analysis:
- score: 15
- messages_bad: []
- messages_good: ['Recommended viewport tag found.', 'Potential responsive CSS (@media, max/min-width) detected in HTML source.']
- searchengine_analysis:
- score: 30
- messages_bad: []
- messages_good: ['Meta description tag found.', 'H1 tag(s) found.', 'Site uses HTTPS.', 'Robots meta tag found: max-image-preview:large']
- meta_description_analysis: ok
Log in to chat with this page.
Social links on the page
- https://twitter.com/MDAorg
- https://www.facebook.com/MDAorg/
- https://www.instagram.com/mdaorg/ https://www.instagram.com/mdaorg/
- https://www.linkedin.com/company/muscular-dystrophy-association/
- https://www.youtube.com/mda https://www.youtube.com/mda
- https://www.youtube.com/watch?v=ksH7zyxBnaA https://www.youtube.com/watch?v=ksH7zyxBnaA
Protected Image
Image Gallery
No images found in the gallery.